治疗后⁶⁸Ga-FAP-2286 PET/CT参数评估¹⁷⁷Lu-FAP-2286放射性配体治疗晚期实体瘤的疗效与生存
本研究回顾性纳入30例完成2周期¹⁷⁷Lu-FAP-2286治疗的晚期实体瘤患者,于治疗后8-16周行⁶⁸Ga-FAP-2286 PET/CT。ΔSUVmax对RECIST 1.1定义的进展期有中等鉴别能力(AUC 0.72,P=0.04),ΔSUVmax<30%组PFS和OS显著更长;多因素分析显示ΔSUVmax是PFS和OS的独立相关因素。
要点
- 治疗后⁶⁸Ga-FAP-2286 PET/CT的ΔSUVmax与治疗反应及生存相关
- ΔSUVmax<30%组中位PFS 10.3个月,≥30%组4.4个月
- ΔSUVmax对RECIST进展期的鉴别AUC为0.72
核心结论
- 在完成2周期¹⁷⁷Lu-FAP-2286治疗的晚期实体瘤患者中,治疗后⁶⁸Ga-FAP-2286 PET/CT的SUVmax变化与治疗反应和生存相关,可能作为早期疗效评估和预后分层的影像生物标志物。
研究设计与样本
- 单中心回顾性研究,纳入完成2周期¹⁷⁷Lu-FAP-2286治疗且基线与治疗后(8-16周)均行⁶⁸Ga-FAP-2286 PET/CT的晚期实体瘤患者,共30例,中位年龄65岁(范围23-78岁)。
- 采用半自动全身分割量化SUVmax和总肿瘤体积(TTV),计算相对变化(ΔSUVmax和ΔTTV),以RECIST 1.1为临床参考标准。
- 采用受试者工作特征分析评估PET参数变化鉴别进展期疾病的能力,采用Kaplan-Meier分析和Cox比例风险模型评估无进展生存期(PFS)和总生存期(OS)。
主要发现
- 根据RECIST 1.1,部分缓解6例(20.0%)、疾病稳定11例(36.7%)、进展期疾病13例(43.3%)。
- 46.7%的患者SUVmax和TTV下降。
- ΔSUVmax对RECIST定义的进展期疾病有中等鉴别能力(AUC 0.72,P=0.04)。
- ΔSUVmax<30%组的中位PFS显著长于ΔSUVmax≥30%组(10.3个月 vs. 4.4个月;log-rank P<0.001)。
- ΔSUVmax<30%组中位OS未达到,ΔSUVmax≥30%组为9.8个月(log-rank P=0.003)。
关键数值与推荐
- ΔSUVmax<30%作为分组阈值,与更长的PFS和OS相关。
- ΔSUVmax对RECIST 1.1进展期疾病的鉴别AUC为0.72(P=0.04)。
临床怎么用
- 对于接受¹⁷⁷Lu-FAP-2286治疗的晚期实体瘤患者,可在治疗后8-16周行⁶⁸Ga-FAP-2286 PET/CT并计算ΔSUVmax,辅助早期疗效评估和预后分层。
- ΔSUVmax≥30%提示预后较差,可考虑更密切的随访或调整治疗策略。
局限性
- 单中心回顾性研究,样本量较小(30例),结果需前瞻性大样本验证。
- 仅纳入完成2周期治疗且行基线与治疗后PET/CT的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fibroblast activation protein (FAP) is highly expressed in cancer-associated fibroblasts and represents an emerging target for radioligand therapy (RLT). This study aimed to evaluate treatment outcomes of ¹⁷⁷Lu-FAP-2286 and to investigate whether changes in quantitative parameters on ⁶⁸Ga-FAP-2286 PET/CT are associated with treatment response and survival in patients with advanced solid tumors. METHODS: In this single-center retrospective study, patients with advanced solid tumors who completed 2 cycles of ¹⁷⁷Lu-FAP-2286 therapy and underwent both baseline and posttreatment ⁶⁸Ga-FAP-2286 PET/CT (8-16 wk after therapy) were included. Maximum standardized uptake value (SUVmax) and total tumor volume (TTV) were quantified using semiautomatic whole-body segmentation. Relative changes (ΔSUVmax and ΔTTV) were calculated. RECIST 1.1 served as the clinical reference standard. Receiver operating characteristic analysis assessed the ability of PET-derived changes to discriminate progressive disease. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS: Thirty patients (median age, 65 y; range, 23-78 y) completed 2 cycles of ¹⁷⁷Lu-FAP-2286 therapy. According to RECIST 1.1, partial response, stable disease, and progressive disease occurred in 6 (20.0%), 11 (36.7%), and 13 (43.3%) patients, respectively. SUVmax and TTV decreased in 46.7% of patients. ΔSUVmax demonstrated moderate discrimination for RECIST-defined PD (AUC 0.72, P =0.04). Patients with ΔSUVmax <30% had significantly longer PFS than those with ΔSUVmax ≥30% (median 10.3 vs. 4.4 mo; log-rank P <0.001). Median OS was not reached in the ΔSUVmax <30% group compared with 9.8 months in the ΔSUVmax ≥30% group (log-rank P =0.003). In multivariable analysis, ΔSUVmax remained independently associated with PFS (HR: 5.2, 95% CI 1.5-7.8; P =0.010) and OS (HR: 4.3, 95% CI: 1.3-14.1; P =0.015). CONCLUSIONS: In patients with advanced solid tumors treated with 2 cycles of ¹⁷⁷Lu-FAP-2286, posttreatment changes in SUVmax on ⁶⁸Ga-FAP-2286 PET/CT were associated with treatment response and survival, suggesting potential utility as an imaging biomarker for early response assessment and prognostic stratification.
引用
- Fan M, Yao Z, Guo X, et al. Posttreatment ⁶⁸Ga-FAP-2286 PET/CT Parameters for Response and Survival Assessment After ¹⁷⁷Lu-FAP-2286 Radioligand Therapy in Advanced Solid Tumors. Clin Nucl Med. 2026. PMID: 42397089. doi:10.1097/RLU.0000000000006588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。